Literature DB >> 18571763

Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice.

Xiaoyan Yin1, Xiuli Cong, Ming Yan, Dong-Er Zhang.   

Abstract

Genetic lesions in chromosomal region 3p21.3 marks one of the earliest events in human lung cancer development. It is hypothesized that one or more tumor suppressor genes reside in this region. Identification and characterization of these genes are important for the understanding of lung cancer initiation. UBE1L (UBA7) is a long-suspected 3p21.3 residing tumor suppressor gene. It encodes the key enzyme that activates ISGylation, a novel, ubiquitination-like, post-translational protein modification system that is inducible by interferon. It has been implicated that ISGylation plays a variety of biological roles ranging from viral defense to tumor surveillance. Here we tested the possible function of ISGylation during lung cancer development by using the Ube1l-deficient mice and the K-ras(LA2) lung cancer mice. Protein ISGylation levels were largely unchanged during lung cancer progression. Ube1l deficiency neither altered the lung cancer progression nor affected the overall survival of K-ras(LA2) lung cancer mice. Our study suggests that Ube1l is not a tumor suppressor gene in K-ras(LA2) lung cancer mouse model. However, as described in the discussion, additional studies with other lung cancer mouse models will be necessary to elucidate the potential tumor suppressor function of UBE1L in K-RAS mutation independent human lung cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571763      PMCID: PMC3137380          DOI: 10.1016/j.lungcan.2008.05.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  40 in total

1.  High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction.

Authors:  Michael P Malakhov; Keun Il Kim; Oxana A Malakhova; Barbara S Jacobs; Ernest C Borden; Dong-Er Zhang
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

Review 2.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

Review 3.  Molecular genetics of small cell lung carcinoma.

Authors:  I I Wistuba; A F Gazdar; J D Minna
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

4.  Recent trends in lung cancer mortality in the United States.

Authors:  A Jemal; K C Chu; R E Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

5.  UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.

Authors:  Sutisak Kitareewan; Ian Pitha-Rowe; David Sekula; Christopher H Lowrey; Michael J Nemeth; Todd R Golub; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

6.  Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia.

Authors:  Ian Pitha-Rowe; Bret A Hassel; Ethan Dmitrovsky
Journal:  J Biol Chem       Date:  2004-02-18       Impact factor: 5.157

Review 7.  Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium.

Authors:  Alexander Yu Nikitin; Ana Alcaraz; Miriam R Anver; Roderick T Bronson; Robert D Cardiff; Darlene Dixon; Armando E Fraire; Edward W Gabrielson; William T Gunning; Diana C Haines; Matthew H Kaufman; R Ilona Linnoila; Robert R Maronpot; Alan S Rabson; Robert L Reddick; Sabine Rehm; Nora Rozengurt; Hildegard M Schuller; Elena N Shmidt; William D Travis; Jerrold M Ward; Tyler Jacks
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

8.  Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor.

Authors:  Makoto Owhashi; Yasuki Taoka; Kazunari Ishii; Shusuke Nakazawa; Haruki Uemura; Hiroji Kambara
Journal:  Biochem Biophys Res Commun       Date:  2003-09-26       Impact factor: 3.575

Review 9.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 10.  Evaluation of the 3p21.3 tumour-suppressor gene cluster.

Authors:  L B Hesson; W N Cooper; F Latif
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  5 in total

1.  Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation.

Authors:  Jun-Bao Fan; Sayuri Miyauchi-Ishida; Kei-ichiro Arimoto; Dan Liu; Ming Yan; Chang-Wei Liu; Balázs Győrffy; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-29       Impact factor: 11.205

Review 2.  Interferon-stimulated gene 15 and the protein ISGylation system.

Authors:  Dongxian Zhang; Dong-Er Zhang
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

3.  Changes in expression of interferon-stimulated genes and ubiquitin activating enzyme E1-like in ovine thymus during early pregnancy.

Authors:  Leying Zhang; Zimo Zhao; Yujiao Wang; Ning Li; Nan Cao; Ling Yang
Journal:  Anim Reprod       Date:  2020-06-29       Impact factor: 1.807

Review 4.  ISG15 and immune diseases.

Authors:  Young Joo Jeon; Hee Min Yoo; Chin Ha Chung
Journal:  Biochim Biophys Acta       Date:  2010-02-12

Review 5.  ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system.

Authors:  Chaohui Zuo; Xinyi Sheng; Min Ma; Man Xia; Linda Ouyang
Journal:  Oncotarget       Date:  2016-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.